Showing results (101-110 of 217) with videos related to
Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapyJosé Baselga, Karen A Gelmon, Shailendra Verma, et al.Cancers|February 26, 2025
NON-SMALL-CELL LUNG CANCER: Real-World Population-Based Cohorts' StudyAlessandra Buja, Massimo Rugge, Alberto Bortolami, et al.The Oncologist|May 31, 2022
Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With OutcomeAlberto Pavan, Alessandra Ferro, Francesco Fortarezza, et al.Biomed Research International|April 23, 2013
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual bloodFilippo Rossignoli, Anna Caselli, Giulia Grisendi, et al.Journal of Neuro-Oncology|March 1, 2018
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancerAmélie Darlix, Gaia Griguolo, Simon Thezenas, et al.European Journal of Cancer (Oxford, England : 1990)|March 9, 2023
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerMark E Robson, Seock-Ah Im, Elzbieta Senkus, et al.Breast (Edinburgh, Scotland)|October 27, 2017
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experienceGaia Griguolo, William Jacot, Eva Kantelhardt, et al.Annals of Surgical Oncology|February 9, 2011
Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancerValentina Guarneri, Annarita Pecchi, Federico Piacentini, et al.Clinical Breast Cancer|October 28, 2008
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278)Valentina Guarneri, Antonio Frassoldati, Paolo Bruzzi, et al.Oncotarget|November 7, 2015
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical dataGiulia Pasello, Loredana Urso, Manlio Mencoboni, et al.Pageof 22